# Cerevel Therapeutics Holdings Inc. (CERE)

Source: https://www.quantisnow.com/company/CERE
Generated: 2026-11-07T00:56:39.862Z

- Ticker: CERE
- Exchange: NASDAQ
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2020
- Website: cerevel.com

## About

Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing CVL-231, a positive allosteric modulator (PAM) that is in Phase Ib clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase II proof-of-concept trials in drug-resistant focal onset seizures in epilepsy or focal onset epilepsy, as well as Phase I proof-of-principle trial for acute anxiety. The company's products also comprise Tavapadon, a selective dopamine D1/D5 partial agonist that is in Phase III clinical trials for the treatment of early- and late-stage Parkinson's disease; CVL-871, a selective dopamine D1/D5 partial agonist for the treatment of dementia-related apathy; and CVL-936, a selective dopamine D3-preferring antagonist, which is in Phase I single ascending dose trials for the treatment of substance use disorder. It is also involved in the development of various preclinical portfolio for various neuroscience indications. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

## Latest CERE news and filings

- 2025-08-13 12:03 UTC [Leadership Update] [Alto Neuroscience Appoints Biotech Industry Veteran, Raymond Sanchez, M.D., to Its Board of Directors](https://www.quantisnow.com/insight/alto-neuroscience-appoints-biotech-industry-veteran-raymond-sanchez-md-to-6162177)
- 2024-08-12 11:30 UTC [SEC Form 15-12G filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-15-12g-filed-by-cerevel-therapeutics-holdings-inc-5653961)
- 2024-08-06 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-cerevel-therapeutics-holdings-inc-5643428)
- 2024-08-06 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-cerevel-therapeutics-holdings-inc-5643426)
- 2024-08-06 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-cerevel-therapeutics-holdings-inc-5643422)
- 2024-08-06 04:15 UTC [SEC Form EFFECT] [SEC Form EFFECT filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-effect-filed-by-cerevel-therapeutics-holdings-inc-5643395)
- 2024-08-05 22:25 UTC [SEC Form 4] [Former 10% Owner Pfizer Inc closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/former-10-owner-pfizer-inc-closing-all-direct-ownership-in-5643147)
- 2024-08-05 22:12 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-cerevel-therapeutics-holdings-5643130)
- 2024-08-05 20:52 UTC [SEC Form 4] [Director Bain Capital Investors Llc returned 65,679,781 shares to the company (SEC Form 4)](https://www.quantisnow.com/insight/director-bain-capital-investors-llc-returned-65679781-shares-to-the-5642816)
- 2024-08-05 20:51 UTC [SEC Form 4] [Director Gordon Christopher R returned 65,693,524 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-gordon-christopher-r-returned-65693524-shares-to-the-company-5642806)
- 2024-08-05 20:49 UTC [SEC Form 4] [Director Koppel Adam returned 65,693,524 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-koppel-adam-returned-65693524-shares-to-the-company-closing-5642780)
- 2024-08-05 20:38 UTC [SEC Form 4] [Chief Medical Officer Sanchez Ramiro returned 14,673 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-sanchez-ramiro-returned-14673-shares-to-the-5642650)
- 2024-08-05 20:36 UTC [SEC Form 4] [Director Giordano Douglas E. returned 13,743 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-giordano-douglas-e-returned-13743-shares-to-the-company-5642638)
- 2024-08-05 20:36 UTC [SEC Form 4] [President & CEO Renaud Ronald C Jr returned 244,309 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/president-ceo-renaud-ronald-c-jr-returned-244309-shares-to-5642630)
- 2024-08-05 20:34 UTC [SEC Form 4] [Director Mckernan Ruth returned 13,743 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-mckernan-ruth-returned-13743-shares-to-the-company-closing-5642609)
- 2024-08-05 20:34 UTC [SEC Form 4] [Chief Legal Officer Akamine Scott returned 7,527 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-legal-officer-akamine-scott-returned-7527-shares-to-the-5642608)
- 2024-08-05 20:32 UTC [SEC Form 4] [Director Sulzberger Gabrielle returned 58,876 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-sulzberger-gabrielle-returned-58876-shares-to-the-company-closing-5642591)
- 2024-08-05 20:30 UTC [SEC Schedule 13D] [Amendment: SEC Form SC 13D/A filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/amendment-sec-form-sc-13da-filed-by-cerevel-therapeutics-holdings-5642577)
- 2024-08-05 20:30 UTC [SEC Form 4] [Chief Scientific Officer Renger John returned 6,370 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-scientific-officer-renger-john-returned-6370-shares-to-the-5642576)
- 2024-08-05 20:30 UTC [SEC Form 4] [Chief Human Resources Officer Dipietro Kenneth returned 25,042 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-human-resources-officer-dipietro-kenneth-returned-25042-shares-to-5642570)
- 2024-08-05 20:29 UTC [SEC Form 4] [Officer Tregoning Kathleen returned 10,666 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-tregoning-kathleen-returned-10666-shares-to-the-company-closing-5642542)
- 2024-08-05 20:28 UTC [SEC Form 4] [Director Dekkers Marijn E returned 444,609 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-dekkers-marijn-e-returned-444609-shares-to-the-company-5642503)
- 2024-08-05 20:26 UTC [SEC Form 4] [Chief Financial Officer Altschuller Susan returned 16,913 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/chief-financial-officer-altschuller-susan-returned-16913-shares-to-the-5642491)
- 2024-08-05 20:24 UTC [SEC Form 4] [Director Riedel Norbert G returned 56,553 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-riedel-norbert-g-returned-56553-shares-to-the-company-5642481)
- 2024-08-05 20:24 UTC [SEC Form 4] [Officer Bodenrader Mark returned 17,724 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-bodenrader-mark-returned-17724-shares-to-the-company-closing-5642473)
- 2024-08-05 20:21 UTC [SEC Form 4] [Director Patrick Deval L returned 13,743 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-patrick-deval-l-returned-13743-shares-to-the-company-5642447)
- 2024-08-05 20:20 UTC [SEC Form 4] [Director Coles N Anthony returned 25,928 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/director-coles-n-anthony-returned-25928-shares-to-the-company-5642442)
- 2024-08-05 20:20 UTC [SEC Form 4] [Officer Burgess Paul D. returned 45,727 shares to the company, closing all direct ownership in the company (SEC Form 4)](https://www.quantisnow.com/insight/officer-burgess-paul-d-returned-45727-shares-to-the-company-5642441)
- 2024-08-01 14:50 UTC [SEC Form 25-NSE filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-25-nse-filed-by-cerevel-therapeutics-holdings-inc-5637528)
- 2024-08-01 13:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-cerevel-therapeutics-holdings-inc-5637439)
- 2024-08-01 13:33 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-cerevel-therapeutics-holdings-inc-5637437)
- 2024-08-01 13:32 UTC [SEC Form S-8 POS] [SEC Form S-8 POS filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-s-8-pos-filed-by-cerevel-therapeutics-holdings-inc-5637435)
- 2024-08-01 13:27 UTC [SEC Form POS AM filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-cerevel-therapeutics-holdings-inc-5637422)
- 2024-08-01 13:26 UTC [SEC Form POS AM filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-cerevel-therapeutics-holdings-inc-5637417)
- 2024-08-01 13:25 UTC [SEC Form POS AM filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-cerevel-therapeutics-holdings-inc-5637413)
- 2024-08-01 13:24 UTC [SEC Form POS AM filed by Cerevel Therapeutics Holdings Inc.](https://www.quantisnow.com/insight/sec-form-pos-am-filed-by-cerevel-therapeutics-holdings-inc-5637409)
- 2024-08-01 12:36 UTC [SEC Form 8-K] [Cerevel Therapeutics Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Material Modification to Rights of Security Holders, Changes in Control of Registrant, Leadership Update, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year](https://www.quantisnow.com/insight/cerevel-therapeutics-holdings-inc-filed-sec-form-8-k-entry-into-5637255)
- 2024-08-01 12:23 UTC [AbbVie Completes Acquisition of Cerevel Therapeutics](https://www.quantisnow.com/insight/abbvie-completes-acquisition-of-cerevel-therapeutics-5637178)
- 2024-07-03 20:05 UTC [SEC Form 4] [Director Coles N Anthony exercised 25,000 shares at a strike of $3.50 and sold $1,029,535 worth of shares (25,000 units at $41.18) (SEC Form 4)](https://www.quantisnow.com/insight/director-coles-n-anthony-exercised-25000-shares-at-a-strike-5593466)
- 2024-07-03 15:58 UTC [Market Chatter] [Cerevel Therapeutics shares are trading lower amid unconfirmed rumors of a recommendation memo from FTC staff to challenge the AbbVie merger.](https://www.quantisnow.com/insight/cerevel-therapeutics-shares-are-trading-lower-amid-unconfirmed-rumors-of-5592710)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/CERE
- Earnings history: https://www.quantisnow.com/earnings/CERE
- Dividend history: https://www.quantisnow.com/dividends/CERE
- Insider transactions: https://www.quantisnow.com/insiders/CERE
- Options chain: https://www.quantisnow.com/options/CERE
- SEC 8-K filings only: https://www.quantisnow.com/company/CERE/8-k
- RSS and alerts for CERE: https://www.quantisnow.com/docs/rss-feeds.md